Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06111235 · ClinicalTrials.gov registry record · Phase 3
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
A Phase 3 study of Bladder Cancer and Urothelial Carcinoma, sponsored by CG Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT06111235: Active Phase 3 study of Bladder Cancer and Urothelial Carcinoma, sponsored by CG Oncology.
NCT06111235 is a Phase 3 study of Bladder Cancer and Urothelial Carcinoma that is active but no longer recruiting, run by CG Oncology. The registered enrollment target is 367 participants, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06111235, a Phase 3 study of Bladder Cancer and Urothelial Carcinoma, is active but no longer recruiting, sponsored by CG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Primary Outcome
Recurrence free survival (RFS) of cretostimogene after TURBT versus surveillance after TURBT
Conditions Studied
Interventions
- DRUG Cretostimogene Grenadenorepvec
- OTHER n-dodecyl-B-D-maltoside
Study Locations (20)
California
- Michael G. Oefelein MD Clinical Trials - Bakersfield
- USC/Keck Department of Urology - Los Angeles
- Tower Urology - Los Angeles
- Sun Kim Urology - Orange
- University of California Irvine Medical Center (UCIMC) - Orange
- University of California Davis Cancer Center - Sacramento
- Stanford University School of Medicine - Stanford
Florida
- Advanced Urology Institute - Daytona Beach
- Mayo Clinic Cancer Center - Jacksonville
- Lakeland Regional Health - Lakeland
- Advanced Urology Institute, LLC - Largo
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic - Scottsdale
- Arizona Institute of Urology PLLC - Tucson
Colorado
- Colorado Clinical Research - Aurora
- Urology Associates, PC - Lone Tree
Alabama
- Urology Centers of Alabama PC - Homewood
Arkansas
- Arkansas Urology PA - Little Rock
Connecticut
- Hartford HealthCare Medical Group - Hartford
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2029-02 |
| Phase | Phase 3 |
What the registry record for NCT06111235 still lists
NCT06111235 is an interventional study that assigns participants to a tested intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cretostimogene Grenadenorepvec is the first listed.
NCT06111235 names 20 study sites across 8 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06111235 about?
NCT06111235 is a clinical study titled "A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT". This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
What is the current status of trial NCT06111235?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2023-12-14. Estimated completion is 2029-02.
What conditions does trial NCT06111235 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Non-muscle Invasive Bladder Cancer, Urologic Cancer.
What interventions are being tested in trial NCT06111235?
The interventions under investigation include: Cretostimogene Grenadenorepvec (DRUG), n-dodecyl-B-D-maltoside (OTHER).
Who is sponsoring clinical trial NCT06111235?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06111235 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06111235's enrollment target sits among peer trials
367 42nd of 175 higher than 134 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI